Learn more

IOVANCE BIOTHERAPEUTICS INC

Overview
  • Total Patents
    209
  • GoodIP Patent Rank
    6,945
  • Filing trend
    ⇧ 102.0%
About

IOVANCE BIOTHERAPEUTICS INC has a total of 209 patent applications. It increased the IP activity by 102.0%. Its first patent ever was published in 2017. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, biotechnology and basic materials chemistry are INTELLIA THERAPEUTICS INC, GENETIC THERAPY INC and FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RES.

Patent filings per year

Chart showing IOVANCE BIOTHERAPEUTICS INCs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Lotze Michael T 68
#2 Wardell Seth 52
#3 Bender James 47
#4 Fardis Maria 34
#5 Chartier-Courtaud Cecile 31
#6 Ritthipichai Krit 29
#7 Rabinovich Brian 18
#8 Karyampudi Lavakumar 17
#9 Michael T Lotze 12
#10 Veerapathran Anand 12

Latest patents

Publication Filing date Title
WO2021081378A1 Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2020232029A1 Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
WO2020180733A1 Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
WO2020146740A1 System and methods for monitoring adoptive cell therapy clonality and persistence
WO2020131547A1 Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
TW202039830A Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
WO2020096927A1 Expansion of tils utilizing akt pathway inhibitors
TW202039829A Selection of improved tumor reactive t-cells
TW202039831A Treatment of nsclc patients refractory for anti-pd-1 antibody
AU2019342749A1 Expansion of tils from cryopreserved tumor samples
TW202031273A Treatment of nsclc patients refractory for anti-pd-1 antibody
WO2019217753A1 Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
AU2019257749A1 Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
CA3090795A1 Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
WO2019136459A1 Processes for generating til products enriched for tumor antigen-specific t-cells
AR115203A1 PROCESSES FOR GENERATING ENRICHED TIL PRODUCTS FOR T-CELL-SPECIFIC TUMOR ANTIGENS
EP3737743A1 Processes for generating til products enriched for tumor antigen-specific t-cells
CA3085765A1 Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
AU2018368786A1 TIL expansion from fine needle aspirates and small biopsies
EP3714041A1 Expansion of peripheral blood lymphocytes (pbls) from peripheral blood